Ascendis Pharma A/S Announces Upcoming Investor Presentations
Details
Event | 2021 |
Location | Virtual |
Date | |
Time |
Event | Morgan Stanley 19th Annual Global Healthcare Conference |
Location | Virtual |
Date | |
Time |
A live webcast of the presentations will be available in the Investors and News section of the
About Ascendis Pharma A/S
The company’s first commercial product based on the company’s proprietary TransCon Technology is SKYTROFA® (lonapegsomatropin-tcgd), approved by the
Ascendis is headquartered in
Please visit www.ascendispharma.com (for global information) or www.ascendispharma.us (for
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Ascendis’ ability to apply its platform technology to build a leading, fully integrated biopharma company, (i) Ascendis’ product pipeline and expansion into additional therapeutic areas and (ii) Ascendis’ expectations regarding its ability to utilize its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers to supply lonapegsomatropin-tcgd, the SKYTROFA® Auto-Injector and other study drug for commercial sales and clinical studies; unforeseen safety or efficacy results in its oncology programs, lonapegsomatropin-tcgd, palopegteriparatide and TransCon CNP or other development programs; unforeseen expenses related to commercialization of SKYTROFA and the further development of lonapegsomatropin-tcgd, expenses related to the development and potential commercialization of its oncology programs, palopegteriparatide and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its oncology programs, lonapegsomatropin-tcgd, palopegteriparatide and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis’ ability to obtain additional funding, if needed, to support its business activities and the effects on its business from the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the
SKYTROFA, Ascendis,
Investor contacts: | Media contact: |
(650) 374-6343 | (650) 709-8875 |
tle@ascendispharma.com | media@ascendispharma.com |
(415) 513-1284 | |
patti.bank@westwicke.com | |
ir@ascendispharma.com |
Source: Ascendis Pharma